 | • レポートコード：TPM-NV171 • 出版社/出版日：Transparency Market Research / 2019年10月28日 • レポート形態：英文、PDF、195ページ • 納品方法：Eメール • 産業分類：製薬 |
| Single User | ￥857,660 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,301,660 (USD8,795) | ▷ お問い合わせ |
| Global Site License | ￥1,745,660 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、全身性炎症反応症候群治療の世界市場について調べ、全身性炎症反応症候群治療の世界市場規模、市場動向、市場シェア、市場環境、市場予測、疾患別（髄膜炎、尿路感染症（UTI）、肺炎、出血、自己免疫疾患、その他）分析、エンドユーザー別（病院および外来手術センター、専門クリニック、その他）分析、関連企業情報などをまとめました。 ・全身性炎症反応症候群治療の市場概要 ・全身性炎症反応症候群治療の市場動向 ・全身性炎症反応症候群治療の世界市場規模・予測 ・全身性炎症反応症候群治療市場：疾患別（髄膜炎、尿路感染症（UTI）、肺炎、出血、自己免疫疾患、その他） ・全身性炎症反応症候群治療市場：エンドユーザー別（病院および外来手術センター、専門クリニック、その他） ・地域別分析（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争環境・関連企業分析 |
The systemic inflammatory response syndrome treatment market is anticipated to grow from ~US$ 9.8 Bn in 2019 to ~US$ 17.8 Bn by 2027, and this healthy growth is attributable to government initiatives taken towards reducing the mortality rate of patients diagnosed with sepsis. Advancements in SIRS therapeutics are further brought in due to investment firms established in developed countries, who fund numerous clinical development programs that possess the capability of formulating effective drugs.
According to the World Health Organization, 7/100 hospitalized patients are highly susceptible to infections, which can cause sepsis. The patient-susceptibility rate in developing countries exceeds even this seven-one-hundred ratio, which signifies profitable opportunities for the systemic inflammatory response syndrome treatment market, as consumers tend to gain financial lucidity along with health consciousness.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Systemic Inflammatory Response Syndrome Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Indication Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, 2017–2027
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Market Outlook
5.1. Technological Advancements
5.2. Key Industry Events (Mergers, Acquisitions, Collaborations, Launch & Approvals, etc.)
5.3. Regulatory Scenario, by Region/Country
5.4. Pipeline Analysis
5.5. Key product/brand Analysis
6. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Indication, 2017–2027
6.3.1. Meningitis
6.3.2. Urinary Tract Infection (UTI)
6.3.3. Pneumonia
6.3.4. Hemorrhage
6.3.5. Autoimmune Diseases
6.3.6. Others
6.4. Market Attractiveness, by Indication
7. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by End-user
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by End-user, 2017–2027
7.3.1. Hospital & Ambulatory Surgical Centers
7.3.2. Specialty Clinics
7.3.3. Others
7.4. Market Attractiveness, by End-user
8. Global Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecasts, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Country/Region
9. North America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Indication, 2017–2027
9.2.1. Meningitis
9.2.2. Urinary Tract Infection (UTI)
9.2.3. Pneumonia
9.2.4. Hemorrhage
9.2.5. Autoimmune Diseases
9.2.6. Others
9.3. Market Value Forecast, by End-user, 2017–2027
9.3.1. Hospital & Ambulatory Surgical Centers
9.3.2. Specialty Clinics
9.3.3. Others
9.4. Market Value Forecast, by Country, 2017–2027
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Indication
9.5.2. By End-user
9.5.3. By Country
10. Europe Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Indication, 2017–2027
10.2.1. Meningitis
10.2.2. Urinary Tract Infection (UTI)
10.2.3. Pneumonia
10.2.4. Hemorrhage
10.2.5. Autoimmune Diseases
10.2.6. Others
10.3. Market Value Forecast, by End-user, 2017–2027
10.3.1. Hospital & Ambulatory Surgical Centers
10.3.2. Specialty Clinics
10.3.3. Others
10.4. Market Value Forecast, by Country/Sub-region, 2017–2027
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Russia
10.4.7. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Indication
10.5.2. By End-user
10.5.3. By Country/Sub-region
11. Asia Pacific Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Indication, 2017–2027
11.2.1. Meningitis
11.2.2. Urinary Tract Infection (UTI)
11.2.3. Pneumonia
11.2.4. Hemorrhage
11.2.5. Autoimmune Diseases
11.2.6. Others
11.3. Market Value Forecast, by End-user, 2017–2027
11.3.1. Hospital & Ambulatory Surgical Centers
11.3.2. Specialty Clinics
11.3.3. Others
11.4. Market Value Forecast, by Country/Sub-region, 2017–2027
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia Pacific
11.5. Market Attractiveness Analysis
11.5.1. By Indication
11.5.2. By End-user
11.5.3. By Country/Sub-region
12. Latin America Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Indication, 2017–2027
12.2.1. Meningitis
12.2.2. Urinary Tract Infection (UTI)
12.2.3. Pneumonia
12.2.4. Hemorrhage
12.2.5. Autoimmune Diseases
12.2.6. Others
12.3. Market Value Forecast, by End-user, 2017–2027
12.3.1. Hospital & Ambulatory Surgical Centers
12.3.2. Specialty Clinics
12.3.3. Others
12.4. Market Value Forecast, by Country/Sub-region, 2017–2027
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Indication
12.5.2. By End-user
12.5.3. By Country/Sub-region
13. Middle East & Africa Systemic Inflammatory Response Syndrome Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Indication, 2017–2027
13.2.1. Meningitis
13.2.2. Urinary Tract Infection (UTI)
13.2.3. Pneumonia
13.2.4. Hemorrhage
13.2.5. Autoimmune Diseases
13.2.6. Others
13.3. Market Value Forecast, by End-user, 2017–2027
13.3.1. Hospital & Ambulatory Surgical Centers
13.3.2. Specialty Clinics
13.3.3. Others
13.4. Market Value Forecast, by Country/Sub-region, 2017–2027
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Israel
13.4.4. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Indication
13.5.2. By End-user
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player – Competition Matrix (By Tier and Size of companies)
14.2. Market Share Analysis, by Company, 2018
14.3. Company Profiles
14.3.1. CytoSorbents Corporation
14.3.1.1. Overview (HQ, Employee Strength, Business Segments)
14.3.1.2. Financials
14.3.1.3. Recent Developments
14.3.1.4. Strategy
14.3.2. RegeneRx Biopharmaceuticals, Inc.
14.3.2.1. Overview (HQ, Employee Strength, Business Segments)
14.3.2.2. Financials
14.3.2.3. Recent Developments
14.3.2.4. Strategy
14.3.3. Endacea, Inc.
14.3.3.1. Overview (HQ, Employee Strength, Business Segments)
14.3.3.2. Strategy
14.3.4. Adrenomed AG
14.3.4.1. Overview (HQ, Employee Strength, Business Segments)
14.3.4.2. Recent Developments
14.3.4.3. Strategy
14.3.5. GlaxoSmithKline plc
14.3.5.1. Overview (HQ, Employee Strength, Business Segments)
14.3.5.2. Financials
14.3.5.3. Recent Developments
14.3.5.4. Strategy
14.3.6. Asahi Kasei Corporation
14.3.6.1. Overview (HQ, Employee Strength, Business Segments)
14.3.6.2. Financials
14.3.6.3. Recent Developments
14.3.6.4. Strategy
14.3.7. Cardinal Health
14.3.7.1. Overview (HQ, Employee Strength, Business Segments)
14.3.7.2. Financials
14.3.7.3. Recent Developments
14.3.7.4. Strategy
14.3.8. Smith & Nephew plc
14.3.8.1. Overview (HQ, Employee Strength, Business Segments)
14.3.8.2. Financials
14.3.8.3. Recent Developments
14.3.8.4. Strategy
14.3.9. ConvaTec, Inc.
14.3.9.1. Overview (HQ, Employee Strength, Business Segments)
14.3.9.2. Financials
14.3.9.3. Recent Developments
14.3.9.4. Strategy
14.3.10. AstraZeneca
14.3.10.1. Overview (HQ, Employee Strength, Business Segments)
14.3.10.2. Financials
14.3.10.3. Recent Developments
14.3.10.4. Strategy
14.3.11. Orion Corporation
14.3.11.1. Overview (HQ, Employee Strength, Business Segments)
14.3.11.2. Financials
14.3.11.3. Recent Developments
14.3.11.4. Strategy
14.3.12. CHIESI Farmaceutici S.p.A.
14.3.12.1. Overview (HQ, Employee Strength, Business Segments)
14.3.12.2. Financials
14.3.12.3. Recent Developments
14.3.12.4. Strategy
14.3.13. Mylan N.V.
14.3.13.1. Overview (HQ, Employee Strength, Business Segments)
14.3.13.2. Financials
14.3.13.3. Recent Developments
14.3.13.4. Strategy
*Note: Financial details of companies that do not report this information in public domain might not have been captured